200 related articles for article (PubMed ID: 33669300)
1. Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia.
Ries J; Agaimy A; Wehrhan F; Baran C; Bolze S; Danzer E; Frey S; Jantsch J; Möst T; Büttner-Herold M; Wickenhauser C; Kesting M; Weber M
Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33669300
[TBL] [Abstract][Full Text] [Related]
2. Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions.
Yagyuu T; Hatakeyama K; Imada M; Kurihara M; Matsusue Y; Yamamoto K; Obayashi C; Kirita T
Oral Oncol; 2017 May; 68():36-43. PubMed ID: 28438290
[TBL] [Abstract][Full Text] [Related]
3. Malignant transformation of oral leukoplakia is associated with macrophage polarization.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Öztürk H; Neubauer K; Wickenhauser C; Kesting M; Ries J
J Transl Med; 2020 Jan; 18(1):11. PubMed ID: 31910881
[TBL] [Abstract][Full Text] [Related]
4. Effect of smoking status and programmed death-ligand 1 expression on the microenvironment and malignant transformation of oral leukoplakia: A retrospective cohort study.
Yagyuu T; Funayama N; Imada M; Kirita T
PLoS One; 2021; 16(4):e0250359. PubMed ID: 33861793
[TBL] [Abstract][Full Text] [Related]
5. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
[TBL] [Abstract][Full Text] [Related]
6. Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study.
Greeshma LR; Joseph AP; Sivakumar TT; Raghavan Pillai V; Vijayakumar G
Sci Rep; 2023 Dec; 13(1):21698. PubMed ID: 38066025
[TBL] [Abstract][Full Text] [Related]
7. Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
Kouketsu A; Sato I; Oikawa M; Shimizu Y; Saito H; Takahashi T; Kumamoto H
J Craniomaxillofac Surg; 2019 Jan; 47(1):33-40. PubMed ID: 30466788
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Preidl R; Neukam FW; Ries J
Oncotarget; 2017 Dec; 8(68):112584-112597. PubMed ID: 29348848
[TBL] [Abstract][Full Text] [Related]
9. [Determination of human papillomavirus in oral leukoplakia,oral lichen planus and oral squamous cell carcinoma].
Cao J; Jin JQ; Deng DJ; Liu HW
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Feb; 48(1):84-8. PubMed ID: 26885914
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
12.
Chen Z; Chen Q; Li S; Tu S; Chen Q; Wang A
Ann Transl Med; 2022 Feb; 10(3):144. PubMed ID: 35284546
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia.
Hanna GJ; Villa A; Mistry N; Jia Y; Quinn CT; Turner MM; Felt KD; Pfaff K; Haddad RI; Uppaluri R; Rodig SJ; Woo SB; Egloff AM; Hodi FS
Cancer Res Commun; 2021 Oct; 1(1):30-40. PubMed ID: 36860910
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of MAGE-A expression and grade of dysplasia for predicting malignant progression of oral leukoplakia.
Ries J; Agaimy A; Vairaktaris E; Kwon Y; Neukam FW; Strassburg LH; Nkenke E
Int J Oncol; 2012 Sep; 41(3):1085-93. PubMed ID: 22751922
[TBL] [Abstract][Full Text] [Related]
15. Progressive increase of human papillomavirus carriage rates in potentially malignant and malignant oral disorders with increasing malignant potential.
Szarka K; Tar I; Fehér E; Gáll T; Kis A; Tóth ED; Boda R; Márton I; Gergely L
Oral Microbiol Immunol; 2009 Aug; 24(4):314-8. PubMed ID: 19572894
[TBL] [Abstract][Full Text] [Related]
16. The relevance of EGFR overexpression for the prediction of the malignant transformation of oral leukoplakia.
Ries J; Vairaktaris E; Agaimy A; Bechtold M; Gorecki P; Neukam FW; Nkenke E
Oncol Rep; 2013 Sep; 30(3):1149-56. PubMed ID: 23784518
[TBL] [Abstract][Full Text] [Related]
17. Role of bcl-2 oncoprotein in oral potentially malignant disorders and squamous cell carcinoma: an immunohistochemical study.
Sudha VM; Hemavathy S
Indian J Dent Res; 2011; 22(4):520-5. PubMed ID: 22124045
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of Bcl-2 and Ki-67 in oral lichen planus and leukoplakia with different degrees of dysplasia.
Pigatti FM; Taveira LA; Soares CT
Int J Dermatol; 2015 Feb; 54(2):150-5. PubMed ID: 25265990
[TBL] [Abstract][Full Text] [Related]
19. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
Luo L; Shu M; Li S; Cai Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
[TBL] [Abstract][Full Text] [Related]
20. PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood.
Wehrhan F; Weber M; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
J Craniomaxillofac Surg; 2021 Feb; 49(2):118-125. PubMed ID: 33358116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
